机构：[1]Department of Urology, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu 610041, Sichuan, China四川大学华西医院[2]Institute of Urology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China610041四川大学华西医院[3]Department of Pathology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China 610041.四川大学华西医院
Due to the significant heterogeneity of renal cell carcinoma (RCC), immune checkpoints may express differently between primary and metastatic tumor. We aimed to evaluate the differential expression of TIM-3 between the primary and metastatic sites of RCC.
Cases of RCC with metastases resected or biopsied at West China Hospital between January 2009 and November 2016 were included. Clinicopathological parameters were retrospectively extracted. SPPS 22.0, GraphPad Prism 6 and R statistical software were applied for data analysis.
A total of 163 cases were included. Immunohistochemical results showed that the overall detection rate of TIM-3 was 56.4% (92/163). The detection rate of TIM-3 in the primary (53.0%, 44/83) was numerically higher than that of the metastasis (42.6%,79/174). Although the concordance rate of TIM-3 between the primary and metastasis was as high as 66.3% (55/83) in the paired cohort, a significant statistically difference of TIM-3 expression between the primary and metastasis was observed (χ2 = 4.664, p = 0.002), with a poor consistency (Kappa = 0.331, p = 0.002). Subsequent survival analysis suggested that TIM-3 expression either in the primary or metastatic tumor was associated with longer progression-free survival (PFS) (HR: 0.67, 95% CI 0.45-0.99, P = 0.02) and overall survival (OS) (HR: 0.52, 95% CI 0.33-0.82, P < 0.001). The expressions of TIM-3 in the primary, metastatic tumors and patients treated with targeted agents all played as favorable factors for PFS and OS. Further multivariate analysis showed that, in the whole cohort, TIM-3 expression in metastatic tumor increased the predicted accuracy (PA) of the whole model of PFS from 74.7 to 75.6% (P = 0.02). For OS, the PA of whole model was increased from 78.1 to 81.1% by adding TIM-3 expression in the metastasis (P = 0.005). The same trends were also observed in paired patients and patients treated with targeted agents. In conclusion, the expression difference between the primary and metastatic tumor of TIM-3 was significant. Biopsy or resection of the metastases may provide a more accurate biological information for clinician's decision-making and the patient's prognosis. What's more, the role of TIM-3 in the RCC still remains controversy, further study are needed to verify the conclusion.
基金：
Natural Science Foundation of China (NSFC
81672547 and 81402110), Science and Technology Support Program of
Sichuan Province (2015SZ0230–3) and 1.3.5 project for disciplines of
excellence, West China Hospital, Sichuan University (No.0040205301E21).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|3 区医学
小类|3 区肿瘤学
最新[2023]版：
大类|2 区医学
小类|3 区肿瘤学
第一作者：
第一作者机构：[1]Department of Urology, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu 610041, Sichuan, China[2]Institute of Urology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China610041
共同第一作者：
通讯作者：
通讯机构：[1]Department of Urology, West China Hospital, Sichuan University, No. 37 Guoxue Xiang, Chengdu 610041, Sichuan, China[2]Institute of Urology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China610041
推荐引用方式(GB/T 7714)：
Zhang Xingming,Yin Xiaoxue,Zhang Haoran,et al.Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma.[J].BMC cancer.2019,19(1):49.doi:10.1186/s12885-019-5273-5.
APA：
Zhang Xingming,Yin Xiaoxue,Zhang Haoran,Sun Guangxi,Yang Yaojing...&Zeng Hao.(2019).Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma..BMC cancer,19,(1)
MLA：
Zhang Xingming,et al."Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma.".BMC cancer 19..1(2019):49
医学